Article Details
Retrieved on: 2025-02-07 22:10:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
AEON Biopharma, a biopharmaceutical firm listed on the NYSE, must submit a compliance plan due to equity deficits. The article discusses their efforts to maintain listing amid financial challenges, relevant to stock exchange regulations and forward-looking statements.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here